REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I have given Novavax, Inc. (NASDAQ: NVAX ) stock three straight Sell recommendations in my last three articles on the Gaithersburg, Maryland-based vaccine maker, in October 2024 , February this year , and mostThe g ...

Healthcare payment concept with stethoscope and big money US dollar.gettyMost Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination. They prefer linear trends—up and to the right.Dividend growers model nicely. Payout “resets” (cuts!) do not. So, there is often a knee-jerk reaction from analysts to sell every divvie slash they see.Same goes for most individual income investors. These vanilla beans sold BlackRock Health Sciences Term Trust (BMEZ) late last week w ...

投资服务内容 - 提供生物技术、制药和医疗保健行业股票的动态跟踪和关键趋势解读 [1] - 为新手和经验丰富的生物技术投资者提供催化剂关注点及买入卖出评级 [1] - 涵盖所有大型制药公司的产品销售和预测、综合财务报表、贴现现金流分析和市场分析 [1] 分析师背景 - 分析师为生物技术顾问 覆盖生物技术、医疗保健和制药行业超过5年 [1] - 分析师已汇编超过1000家公司的详细报告 [1] - 分析师领导投资团体Haggerston BioHealth [1]

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros statement on media inquiry concerning former Board member Schlieren (Zurich), Switzerland, September 18, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, has become aware of a possible imminent publication in a Dutch financial media outlet regarding the recent resignation of Albert Arp, a former member of the company’s Board of Directors. Kuros has received inquiries from the m ...

We recently published 10 Big Names Investors Are Dumping. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the worst performers on Wednesday. Shares of Cytokinetics dropped by 4.42 percent on Wednesday to end at $47.56 apiece after upsizing its senior convertible notes issuance to $650 million. In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise $650 million from the offer, an increase from the $550 million targeted initially. The notes carry a yield rate of 1.75 percent until 2031 and will ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them. Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses ...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday.Following the market opening Thursday, the Dow traded down 0.04% to 46,000.59 while the NASDAQ rose 0.49% to 22,370.12. The S&P 500 also rose, gaining, 0.29% to 6,619.34.Check This Out: This Target Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For ThursdayLeading and Lagging SectorsInformation technology shares jumped by 0.8% on Thursday.In trading on Thursday, materials ...

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

公司活动安排 - 公司将于2025年9月24日太平洋时间上午9:55通过网络直播展示其研发进展 [1] - 管理层将在会议期间与合格投资者进行一对一交流 [2] - 演示实况可通过公司官网投资者专区活动页面观看 [2] 公司业务与技术平台 - 公司为临床阶段生物技术企业 专注于开发新一代细胞与基因疗法 [2] - 核心技术为基因回路平台 可增强治疗精确度与控制性 [2] - 基因回路设计具备四大功能：精准杀伤癌细胞 保护健康细胞 提高靶组织特异性 以及给药后可控性 [2] 研发管线与合作 - 全资管线包含针对血液瘤和实体瘤的细胞疗法 [2] - 临床前数据证实基因回路在NK细胞和T细胞中均有效 [2] - 正通过合作伙伴关系拓展基因回路在非肿瘤领域及其他治疗模式的应用潜力 [2] 信息披露渠道 - 公司通过官方网站及社交媒体平台（X和LinkedIn）发布重大信息 [3] - 披露内容涵盖公司公告 投资者演示材料 SEC文件 新闻稿及会议记录等 [3] - 投资者可通过www.sentibio.com获取最新企业动态 [3]